Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1-Infected, Treatment-Experienced Patients

BACKGROUND: Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity. METHODS: Phase 2, double-blind, randomized study of vicriviroc in treatment-experienced subjects with CCR5-using HIV-1. Vicriviroc (5, 10 or 15 mg) or placebo was added to a failin...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Wilkin, Timothy J., Su, Zhaohui, Krambrink, Amy, Long, Jianmin, Greaves, Wayne, Gross, Robert, Hughes, Michael D., Flexner, Charles, Skolnik, Paul R., Coakley, Eoin, Godfrey, Catherine, Hirsch, Martin, Kuritzkes, Daniel R., Gulick, Roy M.
Format: Artigo
Sprog:Inglês
Udgivet: 2010
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917795/
https://ncbi.nlm.nih.gov/pubmed/20672447
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker